Quote | Verve Therapeutics Inc. (NASDAQ:VERV)
Last: | $6.16 |
---|---|
Change Percent: | -0.64% |
Open: | $6.26 |
Close: | $6.16 |
High: | $6.4094 |
Low: | $6.02 |
Volume: | 785,836 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Verve Therapeutics Inc. (NASDAQ:VERV)
NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NA...
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities are encouraged to obtain additional informat...
Message Board Posts | Verve Therapeutics Inc. (NASDAQ:VERV)
Subject | By | Source | When |
---|---|---|---|
https://cathiesark.com/ | TheFinalCD | investorshub | 02/15/2023 12:03:17 AM |
$VERV IS A GREAT $$$$$ OPPORTUNITY. | crudeoil24 | investorshub | 06/23/2022 7:55:13 PM |
Verve Therapeutics started at outperform with $48 stock | crudeoil24 | investorshub | 06/23/2022 11:26:25 AM |
Verve Therapeutics, Inc. is a genetic medicines company, | crudeoil24 | investorshub | 06/23/2022 11:19:31 AM |
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities are encouraged to obtain additional informat...
2024-04-06 09:50:00 ET Verve Therapeutics (NASDAQ: VERV) saw its shares crater by 36% on April 2 when it reported that a serious mishap had occurred in one of its clinical trials. Understandably, investors may now question whether the gene-editing biotech has a shot at recovering, o...